Enterprise Value

11.69M

Cash

21.61M

Avg Qtr Burn

-3.044M

Short % of Float

2.26%

Insider Ownership

11.16%

Institutional Own.

36.67%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ATRN-119 Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

APR-1051 Details
Solid tumor/s, Cancer

Phase 1

Initiation

Eprenetapopt (APR-246) + azacitidine Details
Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued

Eprenetapopt (APR-246) + Azacitidine Details
Blood disorder, Myelodysplastic syndrome

Failed

Discontinued

APR-548 + azacitidine Details
Mutant Myelodysplastic Syndromes

Failed

Discontinued